SCAI Scientific Sessions 2025 will take place May 1 to 3, at the Walter E. Washington Convention Center in Washington, DC.

Some of the late-breaking topics that will be covered include transcatheter aortic valve replacement (TAVR), peripheral artery disease (PAD), and pulmonary embolism (PE): 

March 11, 2025 — CareDx, Inc. – The Transplant Company – recently announced that AlloSure is now commercially available for pediatric heart transplant patients of all ages and patients who have received a simultaneous pancreas-kidney (SPK) transplant.

Both indications are approved by the New York State Clinical Laboratory Evaluation Program, demonstrating that AlloSure has met the most rigorous validation standards for laboratory developed tests (LDTs).

Broward Health recently announced it is now offering the 

March 12, 2025 – New research from Karl Landsteiner University of Health Sciences (KL Krems) in Austria provides important new insights into how aortic valve size is associated with the degree of valve calcification in severe aortic stenosis (AS).

Mar. 10, 2025-- Corcept Therapeutics Inc., a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, recently announced the initiation of Momentum, a clinical trial examining the prevalence of endogenous hypercortisolism (Cushing’s syndrome) in patients with resistant hypertension. 

March 11, 2025 — The disparities between men and women in prevalence, risk factors and symptoms of peripheral vascular disease (PVD) have a profound impact on prevention, diagnosis, treatment and outcomes for women, according to a new American Heart Association scientific statement published today in the Association’s flagship, peer-reviewed journal Circulation.

March 11, 2025 — Caristo Diagnostics has received U.S. Food and Drug Administration (FDA) 510(k) clearance of its CaRi-Plaque technology, an AI-assisted image analysis application to aid the diagnosis of coronary artery disease (CAD).

At the Cardiovascular Research Technologies (CRT) 2025 conference in Washington, D.C., Medtronic presented new data and clinical milestones across its Coronary, Structural Heart and Renal Denervation businesses.  The conference will showcase key data presentations and advancements across its Coronary, Structural Heart and Renal Denervation businesses in the Medtronic Cardiovascular portfolio. Additionally, Geoff Martha, chief executive officer and chairman at Medtronic, also provided the industry keynote, addressing the company's commitment to advancing cardiovascular care.

Feb. 22, 2025 — More than 60,000 people die from heart valve disease (HVD) in the U.S. each year, according to the American Heart Association 2025 Heart Disease and Stroke Statistical Update. Additionally, data from the Statistical Update shows that more than 28 million people worldwide are living with some type of heart valve disease, an increase of more than 30% in the past decade.

36th Annual Cardiovascular Interventions

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now